# Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

> **NCT00063570** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 73 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00063570
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2009-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063570, "Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00063570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*